Frequently Asked Questions
The market is segmented based on Global Beta-Thalassemia Market, By Type (Beta Thalassemia Minor, Beta Thalassemia Intermedia, Beta Thalassemia Major), Treatment (Iron Chelating Drugs, Erythroid Maturation Agents, Stem Cell Therapy, Blood Transfusion, Others), Diagnosis (Complete Blood Count (CBC), Hemoglobin Electrophoresis with Hemoglobin F and A2 Quantitation, Others), Symptoms (Shortness of Breath, Tiredness, Fast Heartbeat, Moodiness, Jaundice, Slow Growth, Others), Dosage (Injection, Tablets, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.
.
The Global Beta Thalassemia Market size was valued at USD 8.32 USD Billion in 2022.
The Global Beta Thalassemia Market is projected to grow at a CAGR of 8% during the forecast period of 2023 to 2030.
The major players operating in the market include bluebird bio, Protagonist Therapeutics, Agios, Ionis Pharmaceuticals, Vifor Pharma Group, Sangamo Therapeutics, CRISPR Therapeutics.
